Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-03-15
2008-12-30
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S331000, C546S196000, C546S232000
Reexamination Certificate
active
07470711
ABSTRACT:
The present invention relates to piperidine substituted cyclohexane-1,4-diamine compounds of Formula (I)and pharmaceutically acceptable forms thereof, as α1a/α1dadrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as well as method of treatments.
REFERENCES:
patent: 5569659 (1996-10-01), Reitz
patent: 121972 (1984-10-01), None
patent: 03/048118 (2003-06-01), None
Wolff, Manfred E. Burger's Medicinal Chemistry, 5th Ed. Part 1, pp. 975-977 (1995).
Banker et al. “Modern Pharmaceutics”, 3rd Ed. p. 596 (1996).
Testa et al. Pure Appl. Chem. vol. 76, pp. 907-914 (2004).
Vippagunta et al Advanced Drug Delivery Reviews, vol. 48, pp. 3-26 (2001).
Harrison et al., “Molecular characterization of α1- and α2adrenoceptors”, Trends Pharmacol Sci; 1991; 62-67.
Morrow and Creese, “Characterization of α1-Adrenergic Receptor Subtypes in Rat Brain: A Reevaluation of [3H] WB4104 and [3H] Prazosin Binding”, Mol. Pharmacol; 1986; 29:321-330.
Minneman et al., “Comparison of α1-Adrenergic Receptor Subtypes Distinguished by Chlorethylclonidine and WB 4101”, Mol. Pharmacol; 1988; 33:509-514.
Schwinn et al., “Molecular Cloning and Expression of the cDNA for a Novel α1-Adrenergic Receptor Subtype”, J.Biol Chem; 1990; 265: 8183-8189.
Ramaro et al., “Genomic Organization and Expression of the Human α1B-Adrenergic Receptor”, J Biol Chem; 1992; 267:21936-21945.
Bruno et al., “Molecular Cloning and Sequencing of a cDNA Encoding a Human α1A-Adrenergic Receptor”, Biochem Biophys Res Commun; 1991; 179: 1485-1490.
Goetz et al., “BMY 7378 is a selective antagonist of the D subtype of α1-adrenoceptors”, Eur J Pharmacol; 1995; 272:R5-R6.
Caine, “The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy”, J Urol; 1986; 136: 1-4.
Lepor, “Localization of the α1A-adrenoceptor in the human prostate”, J. Urol. 1995, 154, 2096-2099.
Perlberg et al., “Adrenergic Response of Bladder Muscle in Prostatic Obstruction,” Urology; 1982; 20:524-527.
Restorick and Mundy, “The density of cholinergic and alpha and beta adrenergic receptors in the normal and hyper-reflexic human detrusor”, Br J Urol; 1989; 63: 32-35.
Smith and Chapple, “In Vitro Response of Human Bladder Smooth Muscle in Unstable Obstructed Male Bladders: A Study of Pathophysiological Causes,” Neurolog Urodyn; 1994; 12: 414-415.
Walden et al., “Localization of mRNA and receptor binding sites for the α1A-adrenoceptor subtype in the rat, monkey and human urinary bladder and prostate”, J Urol; 1997; 157: 1032-1038.
Malloy et al., “α1-Adrenoceptor Receptor Subtypes in Human Detrusor”, J Urol; 1998; 160: 937-943.
Piascik and Perez, “α1-Adrenergic Receptors: New Insights and Directions”, J Pharmacol Exp Ther; 2001; 298: 403-410.
Danuser and Thor, “Inhibition of central sympathetic and somatic outflow to the lower urinary tract of the cat by the α1-adrenergic receptor antagonist prazosin”, J Urol; 1995; 153: 1308-1312.
Ramage and Wyllie, “A comparison of the effects of doxazosin and terazosin on the spontaneous sympathetic drive to the bladder and related organs in anaesthetized cats”, Eur J Pharmacol; 1995; 294: 645-650.
Ishizuka et al., “Micturition in conscious rats with and without bladder outlet obstruction: role of spinal α1-adrenoceptors”, Br J Pharmacol; 1996; 117:962-966.
Persson et al., “Spinal and peripheral mechanisms contributing to hyperactive voiding in spontaneously hypertensive rats”, Am J Physiol; 1998; 275:R1366-1373.
Steers et al., “The spontaneously hypertensive rat: insight into the pathogenesis of irritative symptoms in benign prostatic hyperplasia and young anxious males”, 1999; Exp Physiol, 1999; 84:137-147.
Smith et al., α1-Adrenergic receptors in human spinal cord: specific localized expression of mRNA encoding “α1-adrenergic receptor subtypes at four distinct levels”, Mol Brain Res; 1999; 63:254-261.
Abrams et al. “Tamsulosin, a selective α1C-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic ‘obstruction’ (symptomatic BPH)”, Br J Urol; 1995; 76:325-336.
Lepor, “Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia”, Urology; 1998; 51:892-900.
Rudner et al., “Subtype Specific Regulation of Human Vascular α1-Adrenergic Receptors by Vessel Bed and Age”, Circulation; 1999; 100:2336-2343.
Lepor, “Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial”, Urology; 1998; 51:901-906.
Heaton, “The serious side of lifestyles issues in urology”, Brit J Urol Int; 2003; 92:875-879.
Habashita, et al. “Preparation of Nitrogen-Containing Heterocyclic Compounds as CXCR4 Regulators' Abstract”. Database CASPLUS on STN (Columbus, OH, USA), No. 141:71555. (2004).
International Search Report, PCT/US06/09192, Sep. 12, 2006.
Harrison et al., “Molecular characterization of α1- and α2adrenoceptors”, Trends Pharmacol Sci; 1991; 62-67.
Morrow and Creese, “Characterization of α1Adrenergic receptor Subtypes in Rat Brain: A Reevaluation of [3H] WB4104 and [3H] Prazosin Binding”, Mol. Pharmacol; 1986; 29:3201-330.
Minneman et al., “Comparison of α1-Adrenergic Receptor Subtypes Distinguished by Chlorethylclonidine and WB 4101”, Mol. Pharmacol; 1998; 33:509-514.
Schwinn et al., “Molecular Cloning and Expression of the cDNA for a Novel α1-Adrenergic Receptor Subtype”, J.Biol Chem; 1990; 265: 8183-8189.
Ramarao et al., “Genomic Organization and Expression of the Human α1B-Adrenergic Receptor”, J Biol Chem; 1992; 267:21936-21945.
Bruno et al., “Molecular Cloning and Sequencing of a cDNA Encoding a Human α1A-Adrenergic Receptor”, Biochem Biophys Res Commun; 1991; 179: 1485-1490.
Goetz et al., “BMY 7378 is a selective antagonist of the D subtype of α1-adrenoceptors”, Eur J Pharmacol; 1995; 272:R5-R6.
Caine, “The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy”, J Urol; 1986; 136: 1-4.
Chiu George
Connolly Peter J.
Li Shengjian
Liu Jingchun
Middleton Steven A.
Bernhardt Emily
Janssen Pharmaceutica N.V.
LandOfFree
Piperidinyl substituted cyclohexane-1,4-diamines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Piperidinyl substituted cyclohexane-1,4-diamines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Piperidinyl substituted cyclohexane-1,4-diamines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4028313